ZCM
FOLD

Zebra Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Zebra Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$137K Buy
+12,352
New +$152K 0.68% 51

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Zebra Capital Management's FOLD Position: Q1 2023 in Review

Zebra Capital Management opened a new position in Amicus Therapeutics (FOLD) in Q1 2023: 12,352 shares worth $137K. The stake represents 0.68% of the portfolio and ranks #51 among its holdings.

226 funds tracked by Wall St. Rank hold FOLD as of Q1 2023.

  • Zebra Capital Management held 12,352 shares of Amicus Therapeutics worth $137K as of Q1 2023.
  • Amicus Therapeutics was a new Zebra Capital Management position in Q1 2023.
  • Amicus Therapeutics made up 0.68% of Zebra Capital Management's portfolio in Q1 2023, its #51 holding.
  • 226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2023.

Based on Zebra Capital Management's 13F filing for Q1 2023, filed 15 May 2023.